370 related articles for article (PubMed ID: 32454036)
21. PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD.
Hu DS; Zhu SH; Liu WY; Pan XY; Zhu PW; Li YY; Zheng KI; Ma HL; You J; Targher G; Byrne CD; Chen YP; Zheng MH
Diabetes Metab; 2020 Nov; 46(6):496-503. PubMed ID: 32035968
[TBL] [Abstract][Full Text] [Related]
22. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
Ajmera V; Perito ER; Bass NM; Terrault NA; Yates KP; Gill R; Loomba R; Diehl AM; Aouizerat BE;
Hepatology; 2017 Jan; 65(1):65-77. PubMed ID: 27532276
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 and liver cirrhosis, chronic calcific pancreatitis, diabetes mellitus, and hypertension among Japanese alcoholic men.
Yokoyama A; Mizukami T; Matsui T; Yokoyama T; Kimura M; Matsushita S; Higuchi S; Maruyama K
Alcohol Clin Exp Res; 2013 Aug; 37(8):1391-401. PubMed ID: 23550892
[TBL] [Abstract][Full Text] [Related]
24. Genetic variation in alcohol dehydrogenase (ADH1A, ADH1B, ADH1C, ADH7) and aldehyde dehydrogenase (ALDH2), alcohol consumption and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
Duell EJ; Sala N; Travier N; Muñoz X; Boutron-Ruault MC; Clavel-Chapelon F; Barricarte A; Arriola L; Navarro C; Sánchez-Cantalejo E; Quirós JR; Krogh V; Vineis P; Mattiello A; Tumino R; Khaw KT; Wareham N; Allen NE; Peeters PH; Numans ME; Bueno-de-Mesquita HB; van Oijen MG; Bamia C; Benetou V; Trichopoulos D; Canzian F; Kaaks R; Boeing H; Bergmann MM; Lund E; Ehrnström R; Johansen D; Hallmans G; Stenling R; Tjønneland A; Overvad K; Ostergaard JN; Ferrari P; Fedirko V; Jenab M; Nesi G; Riboli E; González CA
Carcinogenesis; 2012 Feb; 33(2):361-7. PubMed ID: 22144473
[TBL] [Abstract][Full Text] [Related]
25. Association between ALDH2 and ADH1B Polymorphisms and the Risk for Colorectal Cancer in Koreans.
Choi CK; Shin MH; Cho SH; Kim HY; Zheng W; Long J; Kweon SS
Cancer Res Treat; 2021 Jul; 53(3):754-762. PubMed ID: 33421985
[TBL] [Abstract][Full Text] [Related]
26. Patients with Non-Alcoholic Fatty Liver Disease and Alcohol Dehydrogenase 1B/Aldehyde Dehydrogenase 2 Mutant Gene Have Higher Values of Serum Alanine Transaminase.
Chien TH; Lin CL; Chen LW; Chien CH; Hu CC
J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240928
[TBL] [Abstract][Full Text] [Related]
27. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
28. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
Mitchell T; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Ching H; Hamdorf J; Adams LA
Am J Gastroenterol; 2018 Oct; 113(10):1484-1493. PubMed ID: 29899440
[TBL] [Abstract][Full Text] [Related]
29. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
30. Slow-metabolizing ADH1B and inactive heterozygous ALDH2 increase vulnerability to fatty liver in Japanese men with alcohol dependence.
Yokoyama A; Taniki N; Hara S; Haysashi E; Nakamoto N; Mizukami T; Maruyama K; Yokoyama T
J Gastroenterol; 2018 May; 53(5):660-669. PubMed ID: 29063269
[TBL] [Abstract][Full Text] [Related]
31. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
Guerrerio AL; Colvin RM; Schwartz AK; Molleston JP; Murray KF; Diehl A; Mohan P; Schwimmer JB; Lavine JE; Torbenson MS; Scheimann AO
Am J Clin Nutr; 2012 Apr; 95(4):892-900. PubMed ID: 22338037
[TBL] [Abstract][Full Text] [Related]
32. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study.
Han WM; Apornpong T; Lwin HMS; Thammapiwan S; Boonrungsirisap J; Gatechompol S; Ubolyam S; Tangkijvanich P; Kerr SJ; Avihingsanon A
Clin Infect Dis; 2023 Dec; 77(12):1687-1695. PubMed ID: 37477514
[TBL] [Abstract][Full Text] [Related]
34. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
35. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
36. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
37. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
[TBL] [Abstract][Full Text] [Related]
38. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
[TBL] [Abstract][Full Text] [Related]
39. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
Park JH; Koo BK; Kim W; Kim WH;
Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
[TBL] [Abstract][Full Text] [Related]
40. Hypovitaminosis D is associated with increased whole body fat mass and greater severity of non-alcoholic fatty liver disease.
Dasarathy J; Periyalwar P; Allampati S; Bhinder V; Hawkins C; Brandt P; Khiyami A; McCullough AJ; Dasarathy S
Liver Int; 2014 Jul; 34(6):e118-27. PubMed ID: 24118743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
